Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CLNN 
Clene Inc. (CLNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: CLNN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $27.83
Year Target Price $27.83
| 3 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.15% | Avg. Invested days 18 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.78M USD | Price to earnings Ratio - | 1Y Target Price 27.83 |
Price to earnings Ratio - | 1Y Target Price 27.83 | ||
Volume (30-day avg) - | Beta 0.48 | 52 Weeks Range 2.28 - 7.40 | Updated Date 06/29/2025 |
52 Weeks Range 2.28 - 7.40 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.03 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5032.1% |
Management Effectiveness
Return on Assets (TTM) -49.62% | Return on Equity (TTM) -1738.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45063783 | Price to Sales(TTM) 96.5 |
Enterprise Value 45063783 | Price to Sales(TTM) 96.5 | ||
Enterprise Value to Revenue 128.75 | Enterprise Value to EBITDA -1.13 | Shares Outstanding 8982750 | Shares Floating 6140786 |
Shares Outstanding 8982750 | Shares Floating 6140786 | ||
Percent Insiders 34.6 | Percent Institutions 16.99 |
Analyst Ratings
Rating 4.5 | Target Price 27.83 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Clene Inc.
Company Overview
History and Background
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. Founded in 2012, Clene is headquartered in Salt Lake City, Utah. The company's core technology involves clean-surfaced nanocrystals.
Core Business Areas
- Neurodegenerative Disease Therapies: Developing and commercializing bioenergetic nanocatalysts for neurodegenerative diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinsonu2019s disease.
Leadership and Structure
Rob Etherington serves as the President and CEO. The company operates with a structure typical for a clinical-stage biotech firm, emphasizing research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- CNM-Au8: An oral gold nanocrystal suspension in clinical development for the treatment of multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease. Market share is currently 0% as the product has not been approved by the FDA. Key competitors in these therapeutic areas include Biogen (BIIB), Novartis (NVS), and Teva Pharmaceutical Industries (TEVA).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the neurodegenerative disease treatment sector, is characterized by high unmet medical needs, significant research and development investment, and stringent regulatory oversight. The market is competitive, with numerous companies pursuing innovative therapies.
Positioning
Clene is positioned as a developer of novel nanocatalytic therapies. Its competitive advantage lies in its proprietary technology platform and focus on bioenergetic improvement at the cellular level. However, it faces competition from established pharmaceutical companies with greater resources and approved therapies.
Total Addressable Market (TAM)
The global market for neurodegenerative disease treatments is substantial, estimated at billions of dollars annually and expected to grow significantly. Clene's potential to capture market share depends on the successful completion of its clinical trials and regulatory approval of its therapies. Addressing even a small portion of the overall market will generate significant revenue. However, they are in a very early stage to capture any significant TAM.
Upturn SWOT Analysis
Strengths
- Proprietary nanocrystal technology platform
- Focus on bioenergetic improvement at the cellular level
- Potential for disease-modifying therapies
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with clinical-stage drug development
- Dependence on successful clinical trial outcomes and regulatory approval
- Currently no marketed products and no revenue
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to include other neurodegenerative diseases
- Positive clinical trial results leading to accelerated approval
- Growing demand for effective treatments for neurodegenerative diseases
Threats
- Failure to achieve positive clinical trial results
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Patent challenges and intellectual property infringement
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Novartis (NVS)
- Teva Pharmaceutical Industries (TEVA)
Competitive Landscape
Clene faces intense competition from established pharmaceutical companies. Its competitive advantage lies in its novel technology platform, but it must demonstrate clinical efficacy and navigate a complex regulatory environment to succeed.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as Clene is primarily focused on R&D. Any growth will be directly linked to positive clinical trial results and regulatory approval.
Future Projections: Future projections are highly speculative and dependent on successful clinical trial outcomes and regulatory approval. Analyst estimates should be consulted for specific projections.
Recent Initiatives: Recent initiatives include advancing clinical trials for CNM-Au8 in MS, ALS, and Parkinson's disease, as well as seeking strategic partnerships.
Summary
Clene Inc. is a high-risk, high-reward clinical-stage biopharmaceutical company focused on neurodegenerative diseases. The company's novel nanocrystal technology platform is promising, but success hinges on positive clinical trial outcomes and regulatory approval. The lack of revenue requires the company to continuously raise capital and any negative finding on clinical trials will quickly devalue the stock. Competition from well established pharmaceutical companies present a significant challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Clene Inc. SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is approximate and based on publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clene Inc.
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2020-12-31 | CEO, President & Director Mr. Robert Etherington MBA | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 75 | Website https://clene.com |
Full time employees 75 | Website https://clene.com | ||
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.